Release date: 2014-12-05
Recently, a research paper published in the international magazine JAMA Internal Medicine, researchers from the Albert Einstein College of Medicine revealed that the anti-cholesterol drug rosuvastatin calcium therapy does not decrease. Risk of fracture in male and female individuals with elevated levels of inflammatory markers.
Fractures caused by osteoporosis are a huge problem for aging individuals, and cardiovascular disease (CVD) and osteoporosis may share a biochemical pathway, and many studies have shown fracture risks for statin users. Will be significantly reduced.
In the article, researcher Jessica M. Pena said that we recruited 17,802 male individuals over the age of 50 and female individuals over the age of 60 and studied these participants to test whether statin therapy can reduce the risk of fractures. Highly sensitive C-reactive protein (hs-CRP) inflammatory markers were included in the participants' body, and the marker was at least 2 mg/L. The investigators divided the participants into two groups, one of which was daily. Treated with 20 mg of rosuvastatin, and the other group received placebo.
The researchers said that a total of 431 individuals had fractures in the participants, of which 221 individuals had fractures in the rosuvastatin group, and 210 individuals had fractures in the placebo group; the incidence of fractures in the rosuvastatin group was 1.2 per group. In 100-person years, the incidence of fractures in the placebo group was 1.14 per 100 person-years; in general, higher hs-CRP levels were not associated with an increased risk of individual fracture. This study does not favor the use of statins that prevent cardiovascular disease to reduce the risk of individual fractures.
Source: Bio Valley
Led Light Head,Siren Amplifier,Ambulance Speaker,Electronic Siren Amplifier
jiangyin chenyi medical technology co.,ltd , https://www.chenyimed.com